Loo Keat WeiHeidi SutherlandAnthony AuEmily CamilleriLarisa M. HauptSiew Hua GanLyn R. Griffiths2024-12-312024-12-31201510.1155/2015/167976https://dspace-cris.utar.edu.my/handle/123456789/9357Stroke is a multifactorial disease that may be associated with aberrant DNA methylation profiles. We investigated epigenetic dysregulation for the methylenetetrahydrofolate reductase (<i>MTHFR</i>) gene among ischemic stroke patients. Cases and controls were recruited after obtaining signed written informed consents following a screening process against the inclusion/exclusion criteria. Serum vitamin profiles (folate, vitamin B<sub>12</sub>, and homocysteine) were determined using immunoassays. Methylation profiles for CpGs A and B in the <i>MTHFR</i> gene were determined using a bisulfite-pyrosequencing method. Methylation of <i>MTHFR</i> significantly increased the susceptibility risk for ischemic stroke. In particular, CpG A outperformed CpG B in mediating serum folate and vitamin B<sub>12</sub>levels to increase ischemic stroke susceptibility risks by 4.73-fold. However, both CpGs A and B were not associated with serum homocysteine levels or ischemic stroke severity. CpG A is a potential epigenetic marker in mediating serum folate and vitamin B<sub>12</sub>to contribute to ischemic stroke.A Potential Epigenetic Marker Mediating Serum Folate and Vitamin B<sub>12</sub>Levels Contributes to the Risk of Ischemic Strokejournal-article